Keen on astatine?
Atley Solutions is the global leader in products and services to enable At-211 radiopharmaceuticals.
World leading manufacturing solutions for At-211 radiopharmaceuticals
Astatine-211 represents a breakthrough in targeted radiopharmaceuticals. As a “pure” alpha emitter, nearly all of its emission energy is confined to a highly localized area. This enables precise irradiation of cancer cells while minimizing damage to surrounding healthy tissues. astatine-211 is particularly valuable in treating metastatic cancers, where precision is essential, and where conventional therapies often fall short.
The Atley C100 is the world’s first and only commercial manufacturing system specifically designed for At-211 radiopharmaceuticals. This state-of-the-art platform addresses the critical challenges of At-211 radiopharmaceutical manufacturing, enabling reliable and scalable production from non-clinical R&D to full-scale commercial rollout.
The Atley C100
The Atley C100 module operates in two key stages: purification of At-211 from irradiated targets through dry distillation, followed by automated radiopharmaceutical synthesis and purification.
- Regulatory Compliance: CE mark & CB certificate of compliance to IEC 61010-1.
- At-211 Purification Yield: >80% (n.d.c.).
- At-211 Purification Time: <30 minutes.
News & Knowledge
See all news & knowledgeRichard Zimmermann on the Promise of Astatine-211 in the Future of Nuclear Medicine
Optimizing Astatine-211 Radiolabeling: New Research Highlights the Importance of Timing
Atley installs Atley C100 at world class nuclear medicine research institute Arronax
Atley Solutions and Nusano in collaboration to accelerate astatine-211 development
A breakthrough approach in cancer care
Targeted Alpha Therapy (TAT) employs radiopharmaceuticals designed as precision-guided cancer killers. By binding alpha-emitting isotopes to cancer-specific targeting molecules, TAT delivers high-energy radiation directly to cancer cells, including hard-to-detect micrometastases. The short path length of alpha particles ensures precise irradiation of cancer cells while sparing surrounding healthy tissues. This targeted approach aims to minimize systemic side effects and holds significant potential for improving clinical outcomes, particularly in challenging metastatic cases.
The unique potential of astatine-211
astatine-211 is unlocking new possibilities in targeted alpha therapy. With its unique decay profile, low radiation risk, and covalent bonding chemistry, it enables highly precise cancer treatment with fewer side effects. Its ideal half-life and scalable production make it not only clinically powerful but also practical for real-world use—from outpatient care to global supply.
A partner in radiopharmaceutical innovation
Atley Solutions is built on a strong technical foundation in radiochemistry, automation, and manufacturing. We specialize in the development and manufacturing of At-211-based radiopharmaceuticals, providing the tools and technologies needed to move the next generation of cancer therapies from concept to clinic.
We are unlocking the potential of astatine-211 by combining practical engineering with scientific expertise—delivering scalable, GMP-compliant solutions tailored to the unique demands of targeted alpha therapy. Working closely with researchers, drug developers, and isotope manufacturers, we make At-211-based treatments viable at every stage of development.
